Key clinical point: Creating a database of clinical and genetic information from clinical visits is feasible and useful for oncology research.
Major finding: Among 3,522 patients with advanced disease, the median overall survival was 10.3 months and the 5-year survival rate was 3.8%.
Study details: The study population included 4,064 adults with non–small cell lung cancer.
Disclosures: The study was supported by Flatiron Health and Foundation Medicine, which are both owned by the Roche Group. Dr. Singal and several coauthors are employees of Foundation Medicine.
Singal G et al. JAMA. 2019;321:1391-9.